Semaglutide
- TRADE NAMES: Ozempic (Novo Nordisk); Rybelsus; Wegovy
- INDICATIONS: Antidiabetic. Treatment of type 2 diabetes mellitus.
- CLASS: Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist
- HALF-LIFE: Approximately 1 week
FDA APPROVAL DATE: 12/05/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Insulin, insulin secretagogues
Discontinue semaglutide in women at least 2 months before a planned pregnancy due to the long washout period for this drug.
Not indicated for use in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Semaglutide causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications.
WARNING: RISK OF THYROID C-CELL TUMORS
IN RODENTS, SEMAGLUTIDE CAUSES THYROID C-CELL TUMORS. IT IS UNKNOWN WHETHER SEMAGLUTIDE CAUSES THYROID C-CELL TUMORS, INCLUDING MEDULLARY THYROID CARCINOMA (MTC), IN HUMANS AS THE HUMAN RELEVANCE OF SEMAGLUTIDE-INDUCED RODENT THYROID C-CELL TUMORS HAS NOT BEEN DETERMINED. SEMAGLUTIDE IS CONTRAINDICATED IN PATIENTS WITH A PERSONAL OR FAMILY HISTORY OF MTC OR IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA SYNDROME TYPE 2. COUNSEL PATIENTS REGARDING THE POTENTIAL RISK OF MTC AND SYMPTOMS OF THYROID TUMORS.
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tabs (above) to see two reviews of semaglutide in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/09/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric